OncoSec, UCLA Partner, Use PerkinElmer Tech to Develop Cancer Immune Response Biomarkers | GenomeWeb

NEW YORK (GenomeWeb) — OncoSec Medical, a company developing DNA-based intratumoral cancer immunotherapies, announced today that it is working with the University of California, Los Angeles and PerkinElmer to develop molecular biomarkers to measure patients' immune responses to cancer.

OncoSeq said that the effort will use PerkinElmer’s imaging-based staining methods to quantitatively evaluate CD8+ T cell density, with the goal of developing markers that can distinguish responders from non-responders to anti-PD-1 monotherapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.